Nouri Neamati

List of Publications by Citations

125 papers	3,798 citations	33 h-index	59 g-index
135 ext. papers	4,648 ext. citations	7.4 avg, IF	5.84 L-index

#	Paper	IF	Citations
125	Current Challenges and Opportunities in Treating Glioblastoma. *Pharmacological Reviews*, **2018**, 70, 412-445	22.5	309
124	Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. *Theranostics*, **2017**, 7, 1543-1588	12.1	294
123	In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide. *Journal of the American Chemical Society*, **2013**, 135, 11623-11633	16.4	177
122	Rational design and synthesis of novel dimeric diketoacid-containing inhibitors of HIV-1 integrase: implication for binding to two metal ions on the active site of integrase. *Journal of Medicinal Chemistry*, **2004**, 47, 2561-73	8.3	168
121	Protein disulfide isomerase: a promising target for cancer therapy. *Drug Discovery Today*, **2014**, 19, 222-40	6.8	158
120	Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. *Journal of Medicinal Chemistry*, **2012**, 55, 6645-68	8.3	149
119	Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 16348-53	11.5	149
118	Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. *Retrovirology*, **2009**, 6, 25	3.6	117
117	Design and synthesis of novel indole beta-diketo acid derivatives as HIV-1 integrase inhibitors. *Journal of Medicinal Chemistry*, **2004**, 47, 5298-310	8.3	112
116	A selective mitochondrial-targeted chlorambucil with remarkable cytotoxicity in breast and pancreatic cancers. *Journal of Medicinal Chemistry*, **2013**, 56, 9170-9	8.3	97
115	Discovery of a small-molecule HIV-1 integrase inhibitor-binding site. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 10080-5	11.5	93
114	Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. *Journal of Medicinal Chemistry*, **2005**, 48, 111-20	8.3	91
113	Metal-dependent inhibition of HIV-1 integrase. *Journal of Medicinal Chemistry*, **2002**, 45, 5661-70	8.3	75
112	Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. *Molecular Cancer Therapeutics*, **2013**, 12, 937-49	6.1	73
111	Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga. *Expert Opinion on Therapeutic Patents*, **2002**, 12, 709-724	6.8	69
110	Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer. *Pharmacology & Therapeutics*, **2019**, 195, 111-131	13.9	67
109	Blocking interactions between HIV-1 integrase and cellular cofactors: an emerging anti-retroviral strategy. *Trends in Pharmacological Sciences*, **2007**, 28, 526-35	13.2	62

108	Fragment-based discovery of 8-hydroxyquinoline inhibitors of the HIV-1 integrase-lens epithelium-derived growth factor/p75 (IN-LEDGF/p75) interaction. *Journal of Medicinal Chemistry*, **2013**, 56, 2311-22	8.3	52
107	2,3-Dihydroquinazolin-4(1)-one as a privileged scaffold in drug design.. *RSC Advances*, **2018**, 8, 20894-20921	3.7	49
106	Allosteric inhibitor development targeting HIV-1 integrase. *ChemMedChem*, **2011**, 6, 228-41	3.7	49
105	Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase. *Journal of Medicinal Chemistry*, **2005**, 48, 8009-15	8.3	46
104	New paradigms in drug design and discovery. *Current Topics in Medicinal Chemistry*, **2002**, 2, 211-27	3	45
103	Viral enzymes containing magnesium: Metal binding as a successful strategy in drug design. *Coordination Chemistry Reviews*, **2012**, 256, 3063-3086	23.2	44
102	Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications. *European Urology*, **2018**, 74, 741-753	10.2	43
101	gp130: a promising drug target for cancer therapy. *Expert Opinion on Therapeutic Targets*, **2013**, 17, 1303-28	3.8	43
100	pH-responsive selenium nanoparticles stabilized by folate-chitosan delivering doxorubicin for overcoming drug-resistant cancer cells. *Carbohydrate Polymers*, **2018**, 181, 841-850	10.3	43
99	Design of HIV-1 integrase inhibitors targeting the catalytic domain as well as its interaction with LEDGF/p75: a scaffold hopping approach using salicylate and catechol groups. *Bioorganic and Medicinal Chemistry*, **2011**, 19, 4935-52	3.4	40
98	Structure-based HIV-1 integrase inhibitor design: a future perspective. *Expert Opinion on Investigational Drugs*, **2001**, 10, 281-96	5.9	40
97	Design and discovery of flavonoid-based HIV-1 integrase inhibitors targeting both the active site and the interaction with LEDGF/p75. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 3146-58	3.4	39
96	Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. *Journal of Medicinal Chemistry*, **2011**, 54, 8407-20	8.3	39
95	Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin. *Molecular Oncology*, **2015**, 9, 1799-814	7.9	37
94	Glutathione Transferase Omega-1 Regulates NLRP3 Inflammasome Activation through NEK7 Deglutathionylation. *Cell Reports*, **2019**, 29, 151-161.e5	10.6	34
93	Targeted Nanoparticles for the Delivery of Novel Bioactive Molecules to Pancreatic Cancer Cells. *Journal of Medicinal Chemistry*, **2016**, 59, 5209-20	8.3	34
92	Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor. *Nature Communications*, **2016**, 7, 13084	17.4	32
91	Membrane permeable lipophilic cations as mitochondrial directing groups. *Current Topics in Medicinal Chemistry*, **2015**, 15, 745-66	3	32

90	Discovery of a novel 5-carbonyl-1H-imidazole-4-carboxamide class of inhibitors of the HIV-1 integrase-LEDGF/p75 interaction. *Bioorganic and Medicinal Chemistry*, **2013**, 21, 5963-72	3.4	31
89	Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery. *Cancer Biology and Therapy*, **2010**, 9, 192-203	4.6	31
88	COVID-19: Living through Another Pandemic. *ACS Infectious Diseases*, **2020**, 6, 1548-1552	5.5	29
87	Role of the ERO1-PDI interaction in oxidative protein folding and disease. *Pharmacology & Therapeutics*, **2020**, 210, 107525	13.9	29
86	Activation of the Unfolded Protein Response via Inhibition of Protein Disulfide Isomerase Decreases the Capacity for DNA Repair to Sensitize Glioblastoma to Radiotherapy. *Cancer Research*, **2019**, 79, 2923-2932	10.1	27
85	Design, Synthesis, and Biological Evaluation of 4-Quinoline Carboxylic Acids as Inhibitors of Dihydroorotate Dehydrogenase. *Journal of Medicinal Chemistry*, **2018**, 61, 5162-5186	8.3	27
84	Expression of protein disulfide isomerase family members correlates with tumor progression and patient survival in ovarian cancer. *Oncotarget*, **2017**, 8, 103543-103556	3.3	27
83	Discovery and Mechanistic Elucidation of a Class of Protein Disulfide Isomerase Inhibitors for the Treatment of Glioblastoma. *ChemMedChem*, **2018**, 13, 164-177	3.7	27
82	Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer. *Biochimica Et Biophysica Acta - General Subjects*, **2014**, 1840, 332-43	4	24
81	Design, Synthesis, and Characterization of Brequinar Conjugates as Probes to Study DHODH Inhibition. *Chemistry - A European Journal*, **2017**, 23, 13875-13878	4.8	23
80	Inhibition of protein disulfide isomerase in glioblastoma causes marked downregulation of DNA repair and DNA damage response genes. *Theranostics*, **2019**, 9, 2282-2298	12.1	22
79	Discovery and preclinical evaluation of a novel class of cytotoxic propynoic acid carbamoyl methyl amides (PACMAs). *Journal of Medicinal Chemistry*, **2011**, 54, 2902-14	8.3	22
78	Design and synthesis of novel nitrogen-containing polyhydroxylated aromatics as HIV-1 integrase inhibitors from caffeic acid phenethyl ester. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 4574-8	2.9	22
77	Discovery of Novel CXCR2 Inhibitors Using Ligand-Based Pharmacophore Models. *Journal of Chemical Information and Modeling*, **2015**, 55, 1720-38	6.1	21
76	Tautomeric-Dependent Lactam Cycloaddition with Nitrile Oxide: Facile Synthesis of 1,2,4-Oxadiazole[4,5-]indolone Derivatives. *ACS Omega*, **2017**, 2, 3123-3134	3.9	19
75	Multi-omics profiling reveals key signaling pathways in ovarian cancer controlled by STAT3. *Theranostics*, **2019**, 9, 5478-5496	12.1	18
74	Design and Synthesis of Novel Reactive Oxygen Species Inducers for the Treatment of Pancreatic Ductal Adenocarcinoma. *Journal of Medicinal Chemistry*, **2018**, 61, 1576-1594	8.3	17
73	Design, Synthesis, and Biological Evaluation of Novel Allosteric Protein Disulfide Isomerase Inhibitors. *Journal of Medicinal Chemistry*, **2019**, 62, 3447-3474	8.3	16

72	Pleiotropic Nature of HIV-1 Integrase Mutations67-81		16
71	Molecular Correlates of Responses to Dacomitinib and Afatinib in Bladder Cancer. *Bladder Cancer*, **2018**, 4, 77-90	1	15
70	Why All the Fuss about Oxidative Phosphorylation (OXPHOS)?. *Journal of Medicinal Chemistry*, **2020**, 63, 14276-14307	8.3	15
69	A Novel Redox Modulator Induces a GPX4-Mediated Cell Death That Is Dependent on Iron and Reactive Oxygen Species. *Journal of Medicinal Chemistry*, **2020**, 63, 9838-9855	8.3	15
68	Design and discovery of 5-hydroxy-6-oxo-1,6-dihydropyrimidine-4-carboxamide inhibitors of HIV-1 integrase. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 5446-53	3.4	14
67	The Hydroxyquinoline Analogue YUM70 Inhibits GRP78 to Induce ER Stress-Mediated Apoptosis in Pancreatic Cancer. *Cancer Research*, **2021**, 81, 1883-1895	10.1	14
66	Diketoacid chelating ligands as dual inhibitors of HIV-1 integration process. *European Journal of Medicinal Chemistry*, **2014**, 78, 425-30	6.8	12
65	Pyrimidine-based compounds modulate CXCR2-mediated signaling and receptor turnover. *Molecular Pharmaceutics*, **2014**, 11, 2431-41	5.6	12
64	Selective binding of naphthoquinone derivatives to serum albumin proteins and their effects on cytotoxicity. *Chemico-Biological Interactions*, **2014**, 214, 10-7	5	12
63	Discovery and structure-activity relationship studies of a unique class of HIV-1 integrase inhibitors. *ChemMedChem*, **2006**, 1, 238-44	3.7	12
62	Discovery of novel 3-hydroxypicolinamides as selective inhibitors of HIV-1 integrase-LEDGF/p75 interaction. *European Journal of Medicinal Chemistry*, **2017**, 125, 1051-1063	6.8	11
61	Structural investigation of 3,5-disubstituted isoxazoles by 1H-nuclear magnetic resonance. *Journal of Heterocyclic Chemistry*, **2003**, 40, 1097-1102	1.9	11
60	Structure-Based Design of N-(5-Phenylthiazol-2-yl)acrylamides as Novel and Potent Glutathione S-Transferase Omega 1 Inhibitors. *Journal of Medicinal Chemistry*, **2019**, 62, 3068-3087	8.3	10
59	Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer. *Theranostics*, **2020**, 10, 6959-6976	12.1	10
58	Clinicopathological significance of endoplasmic reticulum stress proteins in ovarian carcinoma. *Scientific Reports*, **2020**, 10, 2160	4.9	10
57	A novel phenylcyclohex-1-enecarbothioamide derivative inhibits CXCL8-mediated chemotaxis through selective regulation of CXCR2-mediated signalling. *British Journal of Pharmacology*, **2014**, 171, 1551-65	8.6	10
56	Dipyrimidine-based inhibitors of HIV-1 integrase. *Expert Opinion on Investigational Drugs*, **2003**, 12, 289-93	3.9	10
55	Metal-Free C-2-H Alkylation of Quinazolin-4-ones with Alkanes via Cross-Dehydrogenative Coupling. *Organic Letters*, **2019**, 21, 2365-2368	6.2	9

54	Synthesis and biological evaluation of novel 2-oxo-1,2-dihydroquinoline-4-carboxamide derivatives for the treatment of esophageal squamous cell carcinoma. *European Journal of Medicinal Chemistry*, **2018**, 155, 516-530	6.8	9
53	Recent advances in the design and discovery of small-molecule therapeutics targeting HER2/neu. *Expert Opinion on Therapeutic Patents*, **2007**, 17, 83-102	6.8	8
52	A Review of Small-Molecule Inhibitors of One-Carbon Enzymes: SHMT2 and MTHFD2 in the Spotlight. *ACS Pharmacology and Translational Science*, **2021**, 4, 624-646	5.9	8
51	Discovery of a Napabucasin PROTAC as an Effective Degrader of the E3 Ligase ZFP91. *Journal of Medicinal Chemistry*, **2021**, 64, 1626-1648	8.3	8
50	TAIJI: approaching experimental replicates-level accuracy for drug synergy prediction. *Bioinformatics*, **2019**, 35, 2338-2339	7.2	7
49	Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines. *European Journal of Medicinal Chemistry*, **2018**, 158, 884-895	6.8	7
48	Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells. *British Journal of Pharmacology*, **2015**, 172, 50-63	8.6	6
47	Deletion of Glutathione S-Transferase Omega 1 Activates Type I Interferon Genes and Downregulates Tissue Factor. *Cancer Research*, **2020**, 80, 3692-3705	10.1	6
46	Alteration of select gene expression patterns in individuals infected with HIV-1. *Journal of Medical Virology*, **2014**, 86, 678-86	19.7	6
45	UAE1 inhibition mediates the unfolded protein response, DNA damage and caspase-dependent cell death in pancreatic cancer. *Translational Oncology*, **2020**, 13, 100834	4.9	6
44	Why All the Fury over Furin?. *Journal of Medicinal Chemistry*, **2021**,	8.3	6
43	Synthesis, ADMET Properties, and Biological Evaluation of Benzothiazole Compounds Targeting Chemokine Receptor 2 (CXCR2). *ChemMedChem*, **2017**, 12, 1045-1054	3.7	5
42	Synthesis, Structure-Activity Relationship Studies, and ADMET Properties of 3-Aminocyclohex-2-en-1-ones as Chemokine Receptor 2 (CXCR2) Antagonists. *ChemMedChem*, **2018** , 13, 916-930	3.7	5
41	The Dihydroorotate Dehydrogenase Inhibitor Brequinar Is Synergistic with ENT1/2 Inhibitors. *ACS Pharmacology and Translational Science*, **2020**, 3, 1242-1252	5.9	5
40	HIV Integrase Inhibitors: From Diketo Acids to Heterocyclic Templates: History of HIV Integrase Medicinal Chemistry at Merck West Point and Merck Rome (IRBM) Leading to Discovery of Raltegravir197-229		5
39	Identification, synthesis and evaluation of CSF1R inhibitors using fragment based drug design. *Computational Biology and Chemistry*, **2019**, 80, 374-383	3.6	4
38	Characterization of Aminobenzylphenols as Protein Disulfide Isomerase Inhibitors in Glioblastoma Cell Lines. *Journal of Medicinal Chemistry*, **2020**, 63, 10263-10286	8.3	4
37	HIV-1 Integrase Inhibitor Design: Overview and Historical Perspectives165-196		4

36	Discovery, structure-activity relationship study and biological evaluation of 2-thioureidothiophene-3-carboxylates as a novel class of C-X-C chemokine receptor 2 (CXCR2) antagonists. *European Journal of Medicinal Chemistry*, **2020**, 204, 112387	6.8	3
35	A small-molecule antagonist of virion assembly. *Expert Opinion on Investigational Drugs*, **2001**, 10, 1767-79	3.9	3
34	Discovery and Lead Optimization of Benzene-1,4-disulfonamides as Oxidative Phosphorylation Inhibitors.. *Journal of Medicinal Chemistry*, **2022**,	8.3	3
33	Role of Metals in HIV-1 Integrase Inhibitor Design287-307		3
32	Structural Studies of Retroviral Integrases35-49		3
31	Inhibition of Human Immunodeficiency Virus-1 Integrase by β-Diketo Acid Coated Gold Nanoparticles. *ACS Medicinal Chemistry Letters*, **2020**, 11, 857-861	4.3	2
30	Dicaffeoyltartaric Acid and Dicaffeoylquinic Acid HIV Integrase Inhibitors341-362		2
29	HIV-1 Integrase–DNA Models429-455		2
28	Preparation of DNA-protein complexes suitable for spectroscopic analysis. *Methods in Molecular Medicine*, **2003**, 85, 185-202		1
27	Development of Styrylquinoline Integrase Inhibitors325-339		1
26	pp32 Is Hot15-21		1
25	Discovery and Development of Natural Product Inhibitors of HIV-1 Integrase309-323		1
24	Cellular Cofactors of HIV Integration105-129		1
23	Functional Interaction between Human Immunodeficiency Virus Type 1 Reverse Transcriptase and Integrase95-103		1
22	Nucleotide-Based Inhibitors of HIV Integrase379-388		1
21	Development of 2,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one inhibitors of aldehyde dehydrogenase 1A (ALDH1A) as potential adjuncts to ovarian cancer chemotherapy. *European Journal of Medicinal Chemistry*, **2021**, 211, 113060	6.8	1
20	Assays for Evaluation of HIV-1 Integrase Enzymatic Activity, DNA Binding, and Cofactor Interaction151-163		1
19	Conformationally Constrained Tricyclic HIV Integrase Inhibitors239-254		1

18	Retroviral Integration Target Site Selection51-65		1
17	Discovery of Mitochondrial Transcription Inhibitors Active in Pancreatic Cancer Cells. *ChemMedChem*, **2020**, 15, 2029-2039	3.7	0
16	Insights into HIV-1 Integrase□DNA Interactions **2011**, 83-94		
15	Azaindole Hydroxamic Acids are HIV-1 Integrase Inhibitors **2011**, 265-274		
14	Targeting HIV-1 Integrase Zinc Binding Motif911-936		
13	Slow-Onset Kinetics of HIV Integrase Inhibitors and Proposed Molecular Model255-263		
12	Application of Protein Covalent Modification to Studying Structure and Function of HIV-1 Integrase and Its Inhibitors415-427		
11	Design and Discovery of Peptide-Based HIV-1 Integrase Inhibitors363-377		
10	Elvitegravir: Novel Quinolone HIV-1 Integrase Strand Transfer Inhibitor231-238		
9	Structural aspects of Lentiviral Integrase□LEDGF Interaction131-140		
8	Resistance to Inhibitors of HIV-1 Integrase477-498		
7	Wiley Series in Drug Discovery and Development507-508		
6	HIV Life Cycle: Targets for Anti-HIV Agents1-14		
5	Integrase Mechanism and Function23-33		
4	Simple and Accurate In Vitro Method for Predicting Serum Protein Binding of HIV Integrase Strand Transfer Inhibitors275-286		
3	Host Factors that affect Provirus Stability and Silencing141-150		
2	New Paradigm for Integrase Inhibition: Blocking Enzyme Function without Directly Targeting the Active Site457-476		
1	Computer-Aided Techniques in Design of HIV-1 Integrase Inhibitors389-413		